|Day Low/High||5.06 / 5.31|
|52 Wk Low/High||3.95 / 8.99|
Investors eyeing a purchase of BioCryst Pharmaceuticals Inc shares, but tentative about paying the going market price of $5.52/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the September put at the $4 strike, which has a bid at the time of this writing of 40 cents.
The most recent short interest data has been released for the 01/31/2018 settlement date, which shows a 1,253,497 share decrease in total short interest for BioCryst Pharmaceuticals Inc , to 10,761,505, a decrease of 10.43% since 01/12/2018. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.
Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.
Analysts see a year of robust deal action ahead due in part to clarity from a tax standpoint.
Novel approach using ALK2 inhibition
The most recent short interest data has been released for the 11/30/2017 settlement date, which shows a 1,191,695 share increase in total short interest for BioCryst Pharmaceuticals, Inc. , to 12,007,211, an increase of 11.02% since 11/15/2017.
The Dublin firm on Nov. 6 unveiled third-quarter numbers that topped analysts' estimates and raised its full-year net sales outlook and the lower end of its 2017 adjusted Ebitda guidance.
Investors considering a purchase of BioCryst Pharmaceuticals, Inc. stock, but tentative about paying the going market price of $5.21/share, might benefit from considering selling puts among the alternative strategies at their disposal.
The approval marks "the first new influenza antiviral for pediatric use in over 10 years," said BioCryst president and CEO Jon Stonehouse in the news release.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.